Publications by authors named "C R Abraham"

Amyloid diseases feature pathologic deposition of normally soluble proteins and peptides as insoluble fibrils in vital organs. Amyloid fibrils co-deposit with various nonfibrillar components including heparan sulfate (HS), a glycosaminoglycan that promotes amyloid formation in vitro for many unrelated proteins. HS-amyloid interactions have been proposed as a therapeutic target for inflammation-linked amyloidosis wherein N-terminal fragments of serum amyloid A (SAA) protein deposit in the kidney and liver.

View Article and Find Full Text PDF

The decline in cervical cancer incidence in the United States has not been uniform and has been influenced by access to care. Hence, we must explore cervical cancer screening routes that do not require a provider visit. This commentary is a call to action that highlights alternatives to cervical cancer screening, specifically the use of self-collected vaginal samples for testing and urine human papillomavirus (HPV) testing.

View Article and Find Full Text PDF

The postpartum period provides an opportunity to improve maternal and infant health, including identifying risks and completing immunization series. Research on completion of varicella and measles, mumps, and rubella (MMR) vaccine series among postpartum mothers is limited. This study examined data from mothers with public health insurance who received prenatal and postpartum care at the Mount Sinai Health System between January 1, 2021, and June 27, 2022.

View Article and Find Full Text PDF

Low-dose chest computed tomography imaging for lung cancer screening is revealing increasing numbers of radiographic early-stage lung cancers. This topic discussion describes when a clinical scenario merits radiation therapy without a histologic diagnosis, with an emphasis on pragmatic algorithms in settings without readily available advanced biopsy techniques.

View Article and Find Full Text PDF
Article Synopsis
  • Avelumab is a treatment approved for patients with advanced urothelial carcinoma (aUC) who did not experience disease progression after platinum-based chemotherapy, based on findings from the JAVELIN Bladder 100 trial.
  • The AVENANCE study included 595 patients and assessed the effectiveness and safety of avelumab as a maintenance therapy, revealing a median overall survival of 21.3 months.
  • The results demonstrated that avelumab is effective in this patient population, reinforcing its role in managing aUC in real-world settings.
View Article and Find Full Text PDF